Hollander D
J Clin Gastroenterol. 1981;3(Suppl 2):153-7.
Sucralfate, a new drug for the treatment of duodenal ulcer, was tested in a multicenter, double-blind, placebo-controlled study. Fifty-five patients with endoscopically documented duodenal ulcers completed the trial successfully. Patients were treated four times daily with 1 g of sucralfate or placebo identical in appearance and taste. They were seen weekly for reinforcement of instructions, assessment of compliance, and clinical evaluation. The patients were reevaluated endoscopically at the end of the second and fourth weeks of therapy. After 4 weeks, 22 of 24 (91.7%) sucralfate-treated patients and 18 of 31 (58.1%) placebo-treated patients showed complete healing of duodenal ulcers (chi 2 = 7.70; p less than 0.01). Relief from ulcer discomfort paralleled the results of healing. We conclude that sucralfate is an effective agent for the treatment of duodenal ulcer.
硫糖铝是一种治疗十二指肠溃疡的新药,在一项多中心、双盲、安慰剂对照研究中进行了测试。55例经内镜证实患有十二指肠溃疡的患者成功完成了试验。患者每天接受4次治疗,服用1克硫糖铝或外观和味道相同的安慰剂。每周对他们进行检查,以强化指导、评估依从性并进行临床评估。在治疗的第二周和第四周结束时,对患者进行内镜复查。4周后,24例接受硫糖铝治疗的患者中有22例(91.7%)十二指肠溃疡完全愈合,31例接受安慰剂治疗的患者中有18例(58.1%)十二指肠溃疡完全愈合(χ² = 7.70;P<0.01)。溃疡不适的缓解情况与愈合结果相似。我们得出结论,硫糖铝是治疗十二指肠溃疡的有效药物。